Bictegravir – A new Integrase Inhibitor in the pipeline
Bictegravir matches dolutegravir for first-line treatment in Phase 2 studies Paul Sax at CROI 2017. Photo by Liz Highleyman, hivandhepatitis.com Bictegravir, an investigational new integrase inhibitor, was highly potent, well tolerated and worked as well as dolutegravir (Tivicay – an existing …
